TGFB1 and systemic sclerosis: Using TGF‐β1 treated normal healthy dermal fibroblasts (NHDFs) and fibroblasts derived from SSc patient skin lesions, we show that TGF‐β1 enhances glycolytic parameters and that inhibition of both glycolysis and glutamine metabolism attenuates the expression of pro‐fibrotic markers.